Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

FR0005175080
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BPCWG0
TNG

Transgene SA
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Transgene SA
ISIN
FR0005175080
TICKER
TNG
MIC
XPAR
REUTERS
TRNG.PA
BLOOMBERG
TNG FP
Tue, 21.01.2025       Transgene

Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllIn...
Tue, 14.01.2025       Transgene

Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its financial reporting dates for 2025:...
Mon, 07.10.2024       Transgene

Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer...
Tue, 24.09.2024       Transgene

TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2024....
Tue, 24.09.2024       Transgene

2024 Half-Year Results and Business Update...
Tue, 24.09.2024       Transgene

2024 Half Year Financial Report...
Sat, 14.09.2024       Transgene

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment...
Mon, 09.09.2024       Transgene

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors....
Tue, 27.08.2024       Transgene

These data, published in The Journal for ImmunoTherapy of Cancer (JITC), demonstrate that TG6050 induces tumor regression and profound remodeling of the tumor microenvironment...
Wed, 31.07.2024       Transgene

Ce communiqué ne peut être publié, transmis ou diffusé ou distribué, directement ou indirectement, aux États-Unis, au Canada, en Australie ou au Japon....
Silent Ad
Tue, 30.07.2024       Transgene

Ce communiqué ne peut être publié, transmis ou diffusé ou distribué, directement ou indirectement, aux États-Unis, au Canada, en Australie ou au Japon....
Mon, 22.07.2024       Transgene

Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and firs...
Wed, 10.07.2024       Transgene

Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of June 30, 2024, the following resources were managed through the liquidity account:...